Streetbeat News

Marketing

MSOS

At the Benzinga Cannabis Capital Conference, CCELL's CMO Angela Pih emphasized the company's commitment to ensuring the quality of the smoking experience in collaboration with its brand partners. The conference also offers live access for both existing and new subscribers.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:27 pm

MRMD

MSOS

At Benzinga's Cannabis Capital Conference, MariMed CCO Howard Schacter discussed the challenges of maintaining product consistency in the cannabis industry. He emphasized the importance of investing in training teams, kitchen, and operations to ensure the delivery of consistent products, even if packaging varies.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:26 pm

MSOS

At Benzinga's Cannabis Capital Conference, Kiva Confections Co-Founder Kristi Palmer discussed the challenges of maintaining a unified brand across different states, specifically mentioning New Jersey's restrictions on cannabis product packaging, which prohibits the use of photos on tins. This has made it difficult to maintain brand consistency.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:25 pm

MSOS

The Benzinga Cannabis Capital Conference discussed the importance of unified branding in the fragmented cannabis market. The conference is available live for existing subscribers, with instant access provided for new users.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:20 pm

CGC

MSOS

MSOX

YOLO

Wana Brands' CMO, Joe Hodas, announced at Benzinga's Cannabis Capital Conference that the company is set to expand its market presence by launching in several new markets and increasing its footprint by more than 25%. Additionally, Wana Brands plans to announce new partnerships.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:12 pm

MSOS

MSOX

YOLO

At Benzinga's Cannabis Capital Conference, Alexa Alianiello from X announced that X became the first mainstream technology platform to support cannabis advertising, enabling hundreds of companies to promote their brands and products.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 1:31 pm

TBLA

Taboola (NASDAQ:TBLA) announced a successful holiday advertising campaign with Bombas, achieving a 300% Return On Ad Spend (ROAS) in November 2023 using Taboola's Maximize Conversions bidding technology. This technology automates CPC bidding to maximize conversions within a specified budget. The campaign resulted in a 224% total ROAS, surpassing the goal by 50%, and a $36 CPA, 49% lower than the target. This collaboration highlights Taboola's role in driving customer acquisition and optimizing campaign spending for Bombas.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 1:19 pm

QCOM

Marques Brownlee's review of the Humane AI Pin has sparked debate on social media about the impact of negative reviews on companies. Brownlee, known as MKBHD, has previously influenced companies like Razer to improve their products. His review of the Humane AI Pin, described as the 'worst product' he's ever reviewed, raises questions about the role of reviews in a product's success. The Humane AI Pin, backed by notable investors including OpenAI's Sam Altman, Tiger Global, and Qualcomm Ventures, is a ChatGPT-powered device.

Portfolio Pulse from Rounak Jain

April 17, 2024 | 1:07 pm

MCHI

Chinese exporters at the Canton Fair are facing challenges despite China's 5.3% economic growth in Q1, including a decline in exports and producer prices. Increased economic and political tensions with the U.S., global trade slowdowns, and manufacturing overcapacity are key issues. Some sectors, like high-tech, remain optimistic due to government support. Trade tensions could worsen with potential U.S. tariffs and blacklisting of Chinese companies. The iShares MSCI China ETF (MCHI) saw a 1.02% dip.

Portfolio Pulse from Benzinga Neuro

April 17, 2024 | 12:58 pm

PTIX

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) announced that COO Dr. Andrew Slee will present on their drug candidate PT00114 at the Peptide Based Therapeutic Summit in Boston on April 23, 2024. The presentation will highlight PT00114's ability to cross the blood-brain barrier, offering potential in neuro-psychiatric treatment. Preclinical data and ongoing clinical safety trial insights will be shared, emphasizing the drug's innovative approach and efficacy.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:47 pm